Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.
Jindani A, Atwine D, Grint D, Bah B, Adams J, Ticona ER, Shrestha B, Agizew T, Hamid S, Jamil B, Byamukama A, Kananura K, Mugisha Taremwa I, Bonnet M, Camara LM, Bah-Sow OY, Bah KS, Bah NM, Sow M, Ticona Huaroto CE, Mugruza Pineda R, Tandukar B, Raya BB, Shrestha N, Mathoma A, Mathebula-Modongo UP, Basotli J, Irfan M, Begum D, Muzammil A, Ahmed I, Hasan R, Burgos MV, Sultan F, Hassan M, Masood I, Robb C, Decker J, Grubnic S, Butcher PD, Witney A, Dhillon J, Munshi T, Fielding K, Harrison TS. Jindani A, et al. NEJM Evid. 2023 Sep;2(9):EVIDoa2300054. doi: 10.1056/EVIDoa2300054. Epub 2023 Aug 22. NEJM Evid. 2023. PMID: 38320155 Clinical Trial.
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. Dheda K, et al. Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Lancet Respir Med. 2019. PMID: 31486393 Review.
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
Francis J, Zvada SP, Denti P, Hatherill M, Charalambous S, Mungofa S, Dawson R, Dorman S, Gupte N, Wiesner L, Jindani A, Harrison TS, Olagunju A, Egan D, Owen A, McIlleron HM. Francis J, et al. Among authors: jindani a. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e01964-18. doi: 10.1128/AAC.01964-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30670438 Free PMC article. Clinical Trial.
Predictors of delayed culture conversion among Ugandan patients.
Atwine D, Orikiriza P, Taremwa I, Ayebare A, Logoose S, Mwanga-Amumpaire J, Jindani A, Bonnet M. Atwine D, et al. Among authors: jindani a. BMC Infect Dis. 2017 Apr 24;17(1):299. doi: 10.1186/s12879-017-2335-7. BMC Infect Dis. 2017. PMID: 28438118 Free PMC article. Clinical Trial.
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
Jindani A, Borgulya G, de Patiño IW, Gonzales T, de Fernandes RA, Shrestha B, Atwine D, Bonnet M, Burgos M, Dubash F, Patel N, Checkley AM, Harrison TS, Mitchison D; International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis, St George's University of London. Jindani A, et al. Int J Tuberc Lung Dis. 2016 Jun;20(6):832-8. doi: 10.5588/ijtld.15.0577. Int J Tuberc Lung Dis. 2016. PMID: 27155189 Clinical Trial.
37 results